HALOZYME THERAPEUTICS, INC. Quarterly Return On Equity in % from Q1 2012 to Q2 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from Q1 2012 to Q2 2024.
  • Halozyme Therapeutics, Inc. Return On Equity for the quarter ending June 30, 2024 was 169 %, a 12.8% decline year-over-year.
  • Halozyme Therapeutics, Inc. annual Return On Equity for 2023 was 205 %, a 108% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Return On Equity for 2022 was 98.6 %, a 59.2% decline from 2021.
  • Halozyme Therapeutics, Inc. annual Return On Equity for 2021 was 242 %, a 93.8% increase from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q2 2024 169 -24.7 -12.8% Apr 1, 2024 Jun 30, 2024
Q1 2024 193 +76.6 +66% Jan 1, 2024 Mar 31, 2024
Q4 2023 205 +106 +108% Oct 1, 2023 Dec 31, 2023
Q3 2023 160 +60 +60.2% Jul 1, 2023 Sep 30, 2023
Q2 2023 193 +51.4 +36.2% Apr 1, 2023 Jun 30, 2023
Q1 2023 116 -86.5 -42.7% Jan 1, 2023 Mar 31, 2023
Q4 2022 98.6 -143 -59.2% Oct 1, 2022 Dec 31, 2022
Q3 2022 99.7 -164 -62.2% Jul 1, 2022 Sep 30, 2022
Q2 2022 142 -67.3 -32.2% Apr 1, 2022 Jun 30, 2022
Q1 2022 203 +48.5 +31.4% Jan 1, 2022 Mar 31, 2022
Q4 2021 242 +117 +93.8% Oct 1, 2021 Dec 31, 2021
Q3 2021 264 +240 +986% Jul 1, 2021 Sep 30, 2021
Q2 2021 209 +241 Apr 1, 2021 Jun 30, 2021
Q1 2021 154 +203 Jan 1, 2021 Mar 31, 2021
Q4 2020 125 +159 Oct 1, 2020 Dec 31, 2020
Q3 2020 24.3 +40.1 Jul 1, 2020 Sep 30, 2020
Q2 2020 -31.7 -14.7 -86.8% Apr 1, 2020 Jun 30, 2020
Q1 2020 -48.9 -28.6 -140% Jan 1, 2020 Mar 31, 2020
Q4 2019 -33.7 -1.85 -5.81% Oct 1, 2019 Dec 31, 2019
Q3 2019 -15.8 -34.6 -184% Jul 1, 2019 Sep 30, 2019
Q2 2019 -17 -55.1 -145% Apr 1, 2019 Jun 30, 2019
Q1 2019 -20.4 -65.7 -145% Jan 1, 2019 Mar 31, 2019
Q4 2018 -31.9 -122 -135% Oct 1, 2018 Dec 31, 2018
Q3 2018 18.9 +911 Jul 1, 2018 Sep 30, 2018
Q2 2018 38.1 -1.03K -96.4% Apr 1, 2018 Jun 30, 2018
Q1 2018 45.3 -454 -90.9% Jan 1, 2018 Mar 31, 2018
Q4 2017 89.8 -8.02K -98.9% Oct 1, 2017 Dec 31, 2017
Q3 2017 -892 -307 -52.5% Jul 1, 2017 Sep 30, 2017
Q2 2017 1.07K +1.43K Apr 1, 2017 Jun 30, 2017
Q1 2017 499 +766 Jan 1, 2017 Mar 31, 2017
Q4 2016 8.11K +8.36K Oct 1, 2016 Dec 31, 2016
Q3 2016 -585 -384 -191% Jul 1, 2016 Sep 30, 2016
Q2 2016 -361 -190 -111% Apr 1, 2016 Jun 30, 2016
Q1 2016 -267 -125 -88.4% Jan 1, 2016 Mar 31, 2016
Q4 2015 -253 -119 -88.5% Oct 1, 2015 Dec 31, 2015
Q3 2015 -201 +38.6 +16.1% Jul 1, 2015 Sep 30, 2015
Q2 2015 -171 +170 +49.9% Apr 1, 2015 Jun 30, 2015
Q1 2015 -142 +525 +78.8% Jan 1, 2015 Mar 31, 2015
Q4 2014 -135 +1.59K +92.2% Oct 1, 2014 Dec 31, 2014
Q3 2014 -240 +59.2 +19.8% Jul 1, 2014 Sep 30, 2014
Q2 2014 -341 -155 -83% Apr 1, 2014 Jun 30, 2014
Q1 2014 -667 -552 -481% Jan 1, 2014 Mar 31, 2014
Q4 2013 -1.73K -1.64K -1917% Oct 1, 2013 Dec 31, 2013
Q3 2013 -299 -172 -135% Jul 1, 2013 Sep 30, 2013
Q2 2013 -187 -96.4 -107% Apr 1, 2013 Jun 30, 2013
Q1 2013 -115 -42.3 -58.2% Jan 1, 2013 Mar 31, 2013
Q4 2012 -85.6 Oct 1, 2012 Dec 31, 2012
Q3 2012 -127 Jul 1, 2012 Sep 30, 2012
Q2 2012 -90.1 Apr 1, 2012 Jun 30, 2012
Q1 2012 -72.6 Jan 1, 2012 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.